StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.37−0.39 (-5.03%)

Close on Nov 16, 2026Market cap $395.25MP/E –Yield –

Avalo Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Avalo Therapeutics's profit margin for the twelve months ending Dec 31, 2025 was -132642.4%. For fiscal 2025 it was -132642.4%, against -7965.8% the year before. The highest annual figure on record is 42.7% in fiscal 2017.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-132642.4%−124676.6
FY2024Dec 31, 2024-7965.8%−6326.3
FY2023Dec 31, 2023-1639.5%−1408.7
FY2022Dec 31, 2022-230.8%+1332.3
FY2021Dec 31, 2021-1563.1%−615.2
FY2020Dec 31, 2020-947.9%−709.8
FY2019Dec 31, 2019-238.1%+331.8
FY2018Dec 31, 2018-569.9%−612.5
FY2017Dec 31, 201742.7%+1471.3
FY2016Dec 31, 2016-1428.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-23254.2%−21039.0
Q4 FY2024Dec 31, 2024-18405.7%−17131.5
Q3 FY2024Sep 30, 20249251.8%+11347.6
Q4 FY2023Dec 31, 2023-1430.5%−335.4
Q3 FY2023Sep 30, 2023-2215.3%−2236.6
Q2 FY2023Jun 30, 2023-1274.2%−17.0
Q1 FY2023Mar 31, 2023-2095.8%−215.9
Q4 FY2022Dec 31, 2022-1095.1%+7670.2
Q3 FY2022Sep 30, 202221.4%+1309.9
Q2 FY2022Jun 30, 2022-1257.2%−747.4
Q1 FY2022Mar 31, 2022-1879.9%+4606.4
Q4 FY2021Dec 31, 2021-8765.3%−7720.3
Q3 FY2021Sep 30, 2021-1288.5%−77.1
Q2 FY2021Jun 30, 2021-509.8%+482.8
Q1 FY2021Mar 31, 2021-6486.3%−5719.5
Q4 FY2020Dec 31, 2020-1045.0%−1324.1
Q3 FY2020Sep 30, 2020-1211.4%−1029.0
Q2 FY2020Jun 30, 2020-992.6%−545.5
Q1 FY2020Mar 31, 2020-766.8%−477.5
Q4 FY2019Dec 31, 2019279.1%+390.6
Q3 FY2019Sep 30, 2019-182.5%+421.3
Q2 FY2019Jun 30, 2019-447.1%−321.5
Q1 FY2019Mar 31, 2019-289.3%−202.7
Q4 FY2018Dec 31, 2018-111.5%+50.2
Q3 FY2018Sep 30, 2018-603.8%−678.6
Q2 FY2018Jun 30, 2018-125.5%+1014.2
Q1 FY2018Mar 31, 2018-86.6%+423.7
Q4 FY2017Dec 31, 2017-161.7%+743.8
Q3 FY2017Sep 30, 201774.8%+1993.6
Q2 FY2017Jun 30, 2017-1139.7%–
Q1 FY2017Mar 31, 2017-510.3%–
Q4 FY2016Dec 31, 2016-905.5%–
Q3 FY2016Sep 30, 2016-1918.8%–

More Avalo Therapeutics figures

See a number that looks wrong?